Q-omics provides the consensus-scored KCNAB3 profile across patient tissues and cancer cell-line models. KCNAB3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCNAB3 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, KCNAB3 RNA expression shows 17,479 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where KCNAB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNAB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNAB3 survival associations across molecular data types. KCNAB3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNAB3 RNA expression–survival associations across cancer types. High KCNAB3 expression shows unfavorable associations in KIRC, ACC and KIRP, but favorable associations in HNSC, PAAD and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCNAB3 RNA expression.
This table summarizes KCNAB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNAB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNAB3 shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, CHOL, STAD and READ. The BLCA box plot shows higher KCNAB3 RNA expression in tumor versus normal tissue (log2 FC = +0.783, t-test p < 0.001).
This table shows molecular features associated with KCNAB3 in patient tissues and cancer cell lines. In patient samples, KCNAB3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNAB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
